Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Manushak Avagyan
Observed names:
Avagyan, Manushak,
M. AVAGYAN,
M. Avagyan,
M., Avagyan,
Manush Avagyan
Institution:
Agenus (United States)
Observed institutions:
American University of Armenia,
Agenus (United States),
Centre international de recherche sur le cancer,
Yerevan State Medical University,
Ludwig-Maximilians-Universität München
ORCID:
0000-0003-2207-3107
Observed ORCID:
0000-0003-2207-3107
OpenAlex ID:
A5047404175
Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas
2025
·
Breelyn A. Wilky
, Gary K. Schwartz
, et al.
·
Journal of Clinical Oncology
·
31
PDF
Risk factors of childhood cancer in Armenia: a case-control study
2023
·
Manushak Avagyan
, Anahit Demirchyan
, et al.
·
BMC Cancer
·
9
PDF
Next-generation CTLA-4 targeting molecules and combination therapy: promising strategies for improving cancer immunotherapy
2023
·
Nils-Petter Rudqvist
, Manushak Avagyan
, et al.
·
OncoImmunology
·
8
PDF
A Phase 1b Study of Botensilimab and Balstilimab in Treatment-Refractory Hepatocellular Carcinoma
2026
·
Anthony B. El-Khoueiry
, Christopher H. Lieu
, et al.
·
Liver Cancer
·
4
PDF
8P Botensilimab plus balstilimab in an expanded cohort of 123 patients with metastatic microsatellite-stable colorectal cancer and no active liver metastases
2025
·
B.L. Schlechter
, M. Fakih
, et al.
·
Annals of Oncology
·
4
PDF
Trends in pediatric CNS tumors in Armenia: a multicenter retrospective study
2023
·
Julieta Hoveyan
, Eduard Asatryan
, et al.
·
Child s Nervous System
·
3
Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
2026
·
Benjamin L. Schlechter
, Marwan G. Fakih
, et al.
·
Clinical Cancer Research
·
2
PDF
Continuing cyclin-dependent kinase 4/6 inhibition in metastatic breast cancer patients previously treated with another cyclin-dependant kinase 4/6 inhibitor: a protocol for systematic review and meta-analysis
2022
·
Alicia de Luna Aguilar
, Javier David Benitez Fuentes
, et al.
·
Research Square
·
2
1726MO Updated efficacy and safety of botensilimab plus balstilimab in patients with refractory metastatic sarcoma from an expanded phase I study
2024
·
B.A. Wilky
, J.C. Trent
, et al.
·
Annals of Oncology
·
1
Secondary Malignancy In Giant Cell Tumor Of The Skull Base After Denosumab Treatment: Case Report
2023
·
M. AVAGYAN
, L. KAGER
, et al.
·
THE NEW ARMENIAN MEDICAL JOURNAL
·
1
PDF
Etmr-07. Etantr: a Rare Tumor in a Resource-limited Setting
2020
·
Julieta Hoveyan
, Manushak Avagyan
, et al.
·
Neuro-Oncology
·
1
Linc-14. Treatment of Pediatric Cns Tumors in Armenia. 10 Years of Experience in a 29 Years Old Resource-limited Setting
2020
·
Martin Harutyunyan
, Lilit Sargsyan
, et al.
·
Neuro-Oncology
·
1
PDF
Table 1 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
2026
·
Benjamin L. Schlechter
, Marwan G. Fakih
, et al.
Figure 3 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
2026
·
Benjamin L. Schlechter
, Marwan G. Fakih
, et al.
Figure 2 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
2026
·
Benjamin L. Schlechter
, Marwan G. Fakih
, et al.
Figure 1 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
2026
·
Benjamin L. Schlechter
, Marwan G. Fakih
, et al.
Data from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
2026
·
Benjamin L. Schlechter
, Marwan G. Fakih
, et al.
Table 3 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
2026
·
Benjamin L. Schlechter
, Marwan G. Fakih
, et al.
C-800-01 Protocol 1 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
2026
·
Benjamin L. Schlechter
, Marwan G. Fakih
, et al.
Supplemental Appendix 1 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
2026
·
Benjamin L. Schlechter
, Marwan G. Fakih
, et al.
Table 2 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
2026
·
Benjamin L. Schlechter
, Marwan G. Fakih
, et al.
C-800-01 SAP 1 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
2026
·
Benjamin L. Schlechter
, Marwan G. Fakih
, et al.
472 Clinical features of long-term survivors treated with next-generation anti–CTLA-4 (botensilimab) plus anti–PD-1 (balstilimab) in refractory microsatellite-stable metastatic colorectal cancer
2026
·
Anthony B El-Khoueiry
, Andrea J Bullock
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
Supplementary Material for: A phase 1b study of botensilimab and balstilimab in treatment-refractory hepatocellular carcinoma
2026
·
karger, figshare admin
, A.B., El-Khoueiry
, et al.
·
Figshare
Abstract LB365: Results from a phase 1 study of botensilimab and balstilimab in treatment refractory hepatocellular carcinoma
2025
·
Anthony B. El-Khoueiry
, Ghassan K. Abou-Alfa
, et al.
·
Cancer Research
Show more works
View as search
Works count:
36
Citation count:
67
H-index:
4
I10-index:
1
Year
Topic
Type
